

## EPOETIN ALFA PRIOR APPROVAL REQUEST

Send completed form to: Service Benefit Plan Prior Approval P.O. Box 52080 MC 139 Phoenix, AZ 85072-2080 Attn. Clinical Services Fax: 1-877-378-4727

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

Patient Information (required)			Provider Information (required)					
Date:				Provider Name:				
Patient Name:				Specialty:	N	NPI:		
Date of Birth: Sex: ☐Male ☐F		□Female	Office Phone:	C	Office Fax:			
Street Address:		I		Office Street Address:				
City:		State:	Zip:	City:	State	:	Zip:	
Patient ID: <b>R</b>	I I			Physician Signature:				
PHYSICIAN COMPLETES								
Retacrit (epoetin alfa-epbx)								
**Check www.fepblue.org/formulary to confirm which medication is part of the patient's benefit								
<b>NOTE</b> : Form must be completed in its <b>entirety</b> for processing								
Note: Approval cannot be given unless all lab values are provided for the diagnosis chosen								
Is this request for brand or generic? □Brand □Generic								
1. Is Retacrit being used in combination with another erythropoiesis stimulating agent (ESA)? □Yes* □No *If YES, please specify the medication:								
2. Has the patient been on Retacrit continuously for the last <b>4 months</b> , excluding samples? □Yes □No*  *If NO, is Retacrit being requested as a change from Procrit to allow the member access to their copay benefit? □Yes □No								
3. What is the pa	3. What is the patient's diagnosis?							
-	bone marrow tran		☐ Anemia asso	ociated with Hepatitis C (HC	CV) treat	tment		
□Myelodyspl	lastic syndrome		☐ Anemia asso	ociated with Rheumatoid Ar	thritis (F	RA)/rheumat	tic disease	
☐ Anemia associated with chronic renal failure								
	_			milliliter (ng/mL)?		-		
			•	otained within the past 3 mo				
c. Has the patient been on Retacrit continuously for the last 4 months, excluding samples? Please select answer below							er below	
□ NO – this is INITIATION of therapy, please answer the following questions:  i. Is the patient on dialysis? <i>Please select answer below:</i>								
☐ Yes: What is the patient's *hemoglobin level in grams per deciliter (g/dL)? g/dL								
*If hemoglobin level is greater than or equal to $10 \text{ g/dL}$ , will the dose be held or reduced until the hemoglobin level is less than 10 grams per deciliter (g/dL)? $\square$ Yes $\square$ No								
□ No: What is the patient's *hemoglobin level in grams per deciliter (g/dL)? g/dL								
*If hemoglobin level is greater than or equal to $11g/dL$ , will the dose be held or reduced until the hemoglobin level is less than 11 grams per deciliter (g/dL)? $\square$ Yes $\square$ No								
☐ YES – this is a PA renewal for CONTINUATION of therapy, please answer the following question(s):								
i. What is the patient's *hemoglobin level in grams per deciliter (g/dL)? g/dL *If hemoglobin level greater than 11 g/dL, will the dose be held or reduced until the hemoglobin level is less than or equal to 11 grams per deciliter (g/dL)? □Yes □No								
☐ Anemia in patients scheduled to undergo elective, non-cardiac, nonvascular surgery								
a. What is the patient's hemoglobin level in grams per deciliter (g/dL)? g/dL								

PLEASE PROCEED TO PAGE 2 FOR ADDITIONAL DIAGNOSES

PAGE 1 of 2



## EPOETIN ALFA PRIOR APPROVAL REQUEST

Send completed form to: Service Benefit Plan Prior Approval P.O. Box 52080 MC 139 Phoenix, AZ 85072-2080 Attn. Clinical Services Fax: 1-877-378-4727

PAGE 2 - PHYSICIAN COMPLETES					
Patient Name:	DOB:	Patient ID: R			
☐ Anemia secondary to chemo	therapy				
a. Is the patient receiving of	concomitant myelosuppresive therap	py? □Yes □No			
b. Are there 2 or more add	itional months of chemotherapy pla	nnned for the patient? □Yes □No			
c. Does the prescriber agree	e to discontinue Retacrit upon comp	pletion of the chemotherapy? □Yes □No			
1	te that transfusions are <b>NOT</b> an option risk bacterial infections)? <b>\(\sigma\)</b> Yes	ion for treatment (i.e., end stage organ failure, chronic kidney □No			
•	dine-treated Human Immunodeficie ous serum erythropoietin levels less t	ency Virus (HIV) patients than or equal to 500 milliunits per milliliter (mU/mL)?			
☐ Other diagnosis (please spec	<i>ify</i> ):				



## BlueShield. EPOETIN ALFA Federal Employee Program. PRIOR APPROVAL REQUEST

Send completed form to: Service Benefit Plan Prior Approval P.O. Box 52080 MC 139 Phoenix, AZ 85072-2080 Attn. Clinical Services Fax: 1-877-378-4727

Message:

Attached is a Prior Authorization request form.

For your convenience, there are 3 ways to complete a Prior Authorization request:

Electronically Online (ePA) Results in 2-3 minutes FASTEST AND EASIEST	Now you can get responses to drug Prior Authorization requests <b>securely</b> online. <b>Online</b> submissions may receive <b>instant</b> responses and do not require faxing or phone calls.  Requests can be made 24 hours a day, 7 days a week. For more information on electronic prior authorization (ePA) and to register, go to <b>Caremark.com/ePA.</b>
Phone (4-5 minutes for response)	The FEP Clinical Call Center can be reached at (877)-727-3784 between the hours of 7AM-9PM Eastern Time. A live representative will assist with the Prior Authorization, asking for the same information contained on the attached form. Please review the form and have your answers ready for faster service.  The process over the phone takes on average between 4 and 5 minutes.
Fax (3-5 days for response)	Fax the attached form to (877)-378-4727. Requests sent via fax will be processed and responded to within 5 business days. The form must be filled out completely, if there is any missing information the Prior Authorization request cannot be processed.  Please only fax the completed form once as duplicate submissions may delay processing times.

faster... easier... better...

Introducing ePA! Online Prior Authorizations in minutes through Caremark.com/ePA. Sign up today!

CVS/caremark

